指南与共识胸部肿瘤放疗放疗物理与技术

ESTRO ACROP 共识:外周型早期非小细胞肺癌立体定向放疗实施与实践指南

ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer.
指南 / 共识 · Radiother Oncol · 2017-07-04

该 ESTRO ACROP 共识基于覆盖 SBRT 实施与实践全部方面的 114 项问卷,由 11 名教员及 8 家机构作答。共识达成风险适应分割推荐:外周病灶 3×15Gy,广泛胸壁接触病灶 4×12Gy,无严重合并症且长期 OS 预期良好者可考虑 3×18Gy。

要点

  • 风险适应分割:外周病灶 3×15Gy,广泛胸壁接触者 4×12Gy。
  • 无严重合并症且长期 OS 预期良好者可考虑最大耐受剂量 3×18Gy。
  • 仅 8/57 技术与技术被认定为必需,而质控相关要素 12/24 项被认为必需。

核心结论

  • 该共识在外周型早期 NSCLC 的 SBRT 实施与实践各方面达成详细推荐,有助于进一步标准化 SBRT。

研究设计与样本

  • 基于覆盖 SBRT 实施与实践全部方面的 114 项问卷,由 ESTRO 课程 11 名教员及 8 家机构作答。

主要发现

  • 超过 50% 机构在全部条目中的 72% 达成一致。
  • 仅 8/57 技术与技术被认定为 SBRT 必需,32/57 被视为可选。
  • 质控相关要素在 12/24 项中被认为必需。

关键数值与推荐

  • 外周病灶推荐 3×15Gy 的风险适应 SBRT 分割。
  • 广泛胸壁接触病灶推荐 4×12Gy(PTV D95-D99;Dmax <125% 至 <150%)。
  • 无严重合并症且长期 OS 预期良好者可考虑最大耐受剂量 3×18Gy。

临床怎么用

  • 按病灶位置与胸壁接触情况选择风险适应分割方案。
  • 优先落实共识认定为必需的质控相关要素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic body radiotherapy (SBRT) has become the standard of care for medically inoperable patients with peripherally located, early stage non-small cell lung cancer (NSCLC), and for those refusing surgical resection. Despite the availability of national and international guidelines, there exists substantial variability in many aspects of SBRT practice. METHODS: The ESTRO ACROP guideline is based on a questionnaire covering all aspects of SBRT implementation and practice (n=114 items). The questionnaire was answered by the 11 faculty members of the ESTRO course "Clinical practice and implementation of image-guided SBRT" and their 8 institutions. RESULTS: Agreement by >50% of the institutions was achieved in 72% of all items. Only 8/57 technologies and techniques were identified as mandatory for SBRT while 32/57 were considered as optional. In contrast, quality-assurance related elements were considered as mandatory in 12/24 items. A consensus of risk-adapted SBRT fractionation was achieved with 3×15Gy for peripherally located lesions and 4×12Gy (PTV D95-D99; Dmax <125% to <150%) for lesions with broad chest wall contact. For patients free from severe comorbidities and with favourable long-term OS expectancy, use of the maximum tolerated dose of 3×18Gy should be considered. CONCLUSIONS: This ACROP guideline achieved detailed recommendations in all aspects of SBRT implementation and practice, which will contribute to further standardization of SBRT for peripherally located early stage NSCLC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Guckenberger M, Andratschke N, Dieckmann K, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol. 2017. PMID: 28687397. doi:10.1016/j.radonc.2017.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。